Sanofi Pasteur (SP), the vaccines business unit of Sanofi, is the largest company in the world devoted entirely to human vaccines. The company produces a portfolio of high quality vaccines that match its areas of expertise and meet public health demand. We distribute more than 1 billion doses of vaccine per year, making it possible to vaccinate more than 500 million people across the globe. Our vaccines protect against 20 infectious diseases: cholera, diphtheria, dengue, haemophilus influenzae type b infections, hepatitis A, hepatitis B, influenza, Japanese encephalitis, measles, meningococcal infections, mumps, pertussis, pneumococcal infections, poliomyelitis, rabies, rubella, tetanus, tuberculosis, typhoid fever and yellow fever. Sanofi Pasteur currently operates fifteen production and/or R&D sites located in France, USA, Canada, Argentina, China, India, Mexico and Thailand. As a key element of Corporate Social Responsibility, Sanofi commits to meet or exceed regulations and standards for the use of animals and to develop alternative approaches. Sanofi fully adheres to the 3Rs principles.
Role of Sanofi Pasteur in the VAC2VAC project
SP will provide overall project input as a member of the scientific management team. For Work Packages 1, 2, 3, and 4, SP will provide input in the selection and development of the methods by advising based on our internal scientific expertise in the field and by providing relevant samples to develop the methods and assess their capability to replace existing methods. In addition, SP will co-lead Work Package 2 and Work Package 4, ensuring the coordination of these two Work Packages. In Work Package 5, SP will contribute to the establishment of common criteria to assess methods development and to the evaluation of the transferability of developed methods by participating to the pre-collaborative studies that will be organized
Moreover, SP will co-lead Work Package 6 by sharing our internal experience on interacting with health authorities and regulators for introducing new methods for the testing of our products as well as for introducing new methods in Regulations.
Sanofi Pasteur is committed to the success of this project which is a unique chance to bring all stakeholders together and overcome global regulatory road blocks in acceptance of novel science-based testing methodologies without the use of animals.
Dr. Laurent Mallet (Associate Vice President, Head of Analytical R&D, Europe) is co-leader for Work Package 6. Laurent Mallet is highly involved in Regulatory Science as he is member of the European Pharmacopoeia group 15 'Sera and vaccines' since 2008.
Dr. Sue Nelson (Director, Analytical Expert 3Rs, Global Analytical Process & Technology) is co-leader for Work Package 2. She has been involved in 3Rs as Director in the Analytical Process & Technology group and now as analytical expert, in charge of ensuring implementation of the 3Rs strategy in Industrial Operations.
Dr. Sylvie Uhlrich (Senior Director, Strategic alignment & expertise, Research & Development) is member of Scientific Management Team and co-leader for Work Package 4. She has been involved in developing 3Rs approaches in analytical R&D and now as analytical expert in charge of strategic alignment for new vaccines.
Eric Abachin, Manager Microbiology Research Unit, Analytical R&D, Europe will contribute to Work package 4.
Nolwenn Nougarede, Director Characterization Immunology & Microbiology platform head, Analytical R&D, Europe will contribute to Work package 3.
Romain Pizzato, Manager Immunology Research Unit, Analytical R&D, Europe will contribute to Work package 2.
Patrice Riou, Director, Virology and Immunology platform head, Analytical R&D, Europe will contribute to Work package 5.
Laurent Thion, Senior Scientist, Analytical R&D, Europe will contribute to Work packages 1, 3 & 4.